Evidence map›Paper›PMID 37727532›Full record

ArticleFrontiers in reproductive health2023

Program impact and potential pitfalls of multi-purpose technologies (MPTs) for HIV prevention and contraception.

Mary H Latka, Kristin Vahle, Kevin Li, Megan Gomes, Anita Dam

Abstract read
In one paragraph

Article in Frontiers in reproductive health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mary H LatkaOffice of HIV/AIDS, Bureau of Global Health, United States Agency for International Development, Washington, DC, United States.
Kristin VahleOffice of HIV/AIDS, Bureau of Global Health, United States Agency for International Development, Washington, DC, United States.
Kevin LiOffice of HIV/AIDS, Bureau of Global Health, United States Agency for International Development, Washington, DC, United States.
Megan GomesOffice of Population and Reproductive Health, Bureau of Global Health, United States Agency for International Development, Washington, DC, United States.
Anita DamOffice of HIV/AIDS, Bureau of Global Health, United States Agency for International Development, Washington, DC, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The overlapping epidemics of HIV and unplanned pregnancy disproportionately affect adolescent girls and young women (AGYW) in sub-Saharan Africa. Prevailing dynamics driving benefits of any prevention method at the population level depend on: 1) population size, risk profile, and prevalence of method use, 2) method efficacy, and 3) method use-effectiveness. Adding a multi-purpose technology (MPT) to prevent HIV and pregnancy to this three-part equation results in scenarios that may enhance HIV population impact, even with methods that exhibit less than "perfect" method efficacy, by extending protection among existing users and attracting new users, resulting in greater population coverage. However, the interplay of epidemic drivers is complex and the greatest population benefit of such a MPT would be realized among those most at risk for HIV and pregnancy, and could be harmful if successful contraceptive users switch to a method with lower use-effectiveness. While MPTs are highly desired, and may offer considerable individual, population, and system-level public health benefits, there is no "magic bullet", nor single prevention method-MPT or otherwise-that will end the HIV epidemic nor fully resolve unmet need for family planning. All methods have inherent tradeoffs and women have varied reproductive and HIV prevention needs across their life course. Key programmatic features to maximize the potential of MPTs include offering them among a range of safe and effective methods with comprehensive information about their features allowing women to make a fully-informed method choice. Programmatic follow-up should support consistent and correct use to maximize use-effectiveness, and then monitor for potential untoward effects.

Indexed as

adolescent girlscontraceptionHIV preventionmethod efficacymulti-purpose technologysub-Saharan Africaunplanned pregnancyuse-effectiveness

Identifiers

PMID37727532
PMCPMC10505718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.